PER-007-04已完成未知
6-WEEK MULTICENTER STUDY, RANDOMIZED, A DOUBLE-BLIND, PLACEBO-CONTROLLED AND SIMILARLY APPEARED MEDICATIONS, TO EVALUATE THE EFFECT OF TEGASEROD ADMINISTERED AT DOSES OF 2 MG THREE TIMES PER DAY AND 6MG DISPPSY IN DIABETIC PATIENTS WITH SYMPTOMS OF DIABETIC GASTROPATHY.
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 0 人开始时间: 2004年4月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Men and women between 18 to 65 years of age.
- •2. With a history of diabetes mellitus type 1 and type 2 with insulin requirement for at least 3 years; and a history of dyspeptic symptoms due to diabetic gastropathy.
- •3. Those who agree to maintain their diet and exercise level prior to the study throughout the course of it.
排除标准
- •1. Those with an abnormal high gastrointestinal endoscopy performed during the 6 months prior to selection.
- •2. With conditions that are known to affect gastric emptying.
- •3. With erosive esophagitis, gastric ulcer or duodenal ulcer.
研究者
相似试验
招募中
1 期
A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the body when taken by children with chronic kidney disease and proteinuria in addition to angiotensin-converting enzyme inhibitor or angiotensin receptor blockerCTIS2023-504884-17-00Bayer AG457
进行中（未招募）
不适用
A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder.MedDRA version: 12.0Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive DisorderEUCTR2009-011200-39-EEGlaxoSmithKline Research & Development Ltd180
进行中（未招募）
不适用
A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder.Major Depressive DisorderEUCTR2009-011200-39-BGGlaxoSmithKline Research & Development Ltd180
进行中（未招募）
不适用
A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder.MedDRA version: 12.0Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive DisorderEUCTR2009-011200-39-DEGlaxoSmithKline Research & Development Ltd180
进行中（未招募）
不适用
A 6-week multicenter, randomized, double-blind, placebo-controlled, parallel group effficacy trial of 2 different dose regimens of lumiracoxib (100 mg bid and 200 mg od)in patients with primary knee osteoarthritis using naproxen 500 mg bid as a positive controlEUCTR2004-002434-19-ITOVARTIS FARMA916